Jasper Therapeutics, Inc. (JSPR)

Market Cap	18.81M
Revenue (ttm)	n/a
Net Income	n/a
EPS	n/a
Shares Out	33.27M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	237,386
Open	0.6000
Previous Close	0.5980
Day's Range	0.5625 - 0.6150
52-Week Range	0.3151 - 2.6900
Beta	3.17
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 9, 2026

About JSPR

Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 22
• Stock Exchange: Nasdaq
• Ticker Symbol: JSPR
• Website: https://jaspertx.com

Financial Performance

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 3, 2026

Data Sources Report a data error